Feature | February 07, 2014

Transcatheter Pump May Aid Heart Failure Patients

Procyrion Aortix Ventricular Assist Device Hemodynamic Support Heart Failure
February 7, 2014 — Start-up company Procyrion Inc. is developing a catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. The 6-mm diameter Aortix device is narrower than a pencil and is delivered via a catheter in a minimally invasive outpatient procedure lasting about 10 minutes.
 
Currently, long-term mechanical circulatory support (MCS) is limited to large ventricular assist devices (VADs). These devices are mainly used in patients with late stage heart failure (HF). Procyrion is developing a percutaneous intra-aortic micro-axial fluid entrainment pump called Aortix intended for long-term MCS in patients with earlier stage HF.
 
Aortix has been successfully tested with computer models, on the bench top in mock flow loops and in vivo in large animal HF studies. In three porcine experiments conducted last year, the pump was deployed in the thoracic aorta by standard cardiac catheterization techniques and was anchored with self-expanding struts. Acute cardiac dysfunction was induced by infusing esmolol continuously. Pump support increased cardiac output (+10.4 percent), stroke volume (+8.9 percent), and ejection fraction (+10.8 percent) while decreasing cardiac stroke work (-10.8 percent) and afterload (-22.7 percent). Pump support enhanced renal perfusion through sustained increases in both renal artery flow (+36.4 percent) and pressure (+73.6 percent).
 
In a porcine model of acute HF, the catheter-based intra-aortic fluid entrainment pump improved hemodynamics and renal perfusion. These results suggest the pump could improve HF outcomes and patients' quality of life by resting the heart, promoting reverse remodeling and augmenting end-organ perfusion. The renal perfusion may help disrupt the cardiorenal syndrome cycle and improve HF treatment.
 
The company received the Commercialization award by the Gulf Coast Regional Center of Innovation and Commercialization in February 2013 and received a total of $1.5 million in assistance from the Texas Emerging Technology Fund.  
 
 
For more information: www.procyrion.com

Related Content

Heart Failure Mortality Inversely Related to Wealth of Country
News | Heart Failure| May 24, 2017
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late...
News | Heart Failure| May 22, 2017
Serelaxin failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late-breaking results...
WiSE CRT System is a wireless cardiac resynchonization therapy device with no lead wires

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional Cardiac Resynchronization Therapy (CRT) in heart failure patients.

News | Heart Failure| May 12, 2017
May 12, 2017 – New study proves safety of novel, wireless pacing system, WiSE CRT (Wireless Stimulation Endocardially
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
American Regent Announces Enrollment of First Patient in Phase 3 HEART-FID Trial
News | Heart Failure| May 03, 2017
American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the...
Technology | Intra-Aortic Balloon Pumps (IABP)| May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Overlay Init